Jazz Pharmaceuticals (JAZZ)
Create an AlertJAZZ Key Stats
| Income Statement | |
| Revenue TTM | 684.99M |
| Revenue Quarterly YoY Growth | 91.39% |
| EPS Diluted TTM | 4.985 |
| EPS Diluted Quarterly YoY Growth | 47.92% |
| Net Income TTM | 304.33M |
| Profitability | |
| Gross Profit Margin Quarterly | 86.13% |
| Profit Margin Quarterly | 22.13% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 4.125B |
| Enterprise Value | 4.126B |
| PE Ratio TTM | 14.05 |
| PE 10 Pro | Go Pro |
| PEG Ratio | 0.1621 |
| Price / Book Value | 3.551 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.3883 |
| Free Cash Flow | 63.45M |
| Return on Equity | 31.82% |
JAZZ News
- ViroPharma Up on Takeover Rumors Jun 18
- Positive Data on Incyte's Jakafi Jun 18
- Acquisitions Add To Jazz Pharma's Diversity Jun 18
- Data on Astex Candidate Jun 18
- Ariad's Iclusig in GIST Phase II Study Jun 18
- MannKind Completes Afrezza Studies Jun 18
- ViroPharma Up on Takeover Rumors - Analyst Blog Zacks Jun 18
- Positive Data on Incyte's Jakafi - Analyst Blog Zacks Jun 18
- Data on Astex Candidate - Analyst Blog Zacks Jun 18
- Ariad's Iclusig in GIST Phase II Study - Analyst Blog Zacks Jun 18
JAZZ Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Jazz Pharmaceuticals is up 56.60% over the last year vs S&P 500 Total Return up 25.82%, Santarus up 220.7%, and Cubist Pharmaceuticals up 27.54%.
JAZZ Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Cash Flow Statement View Statement
You may also be interested in these JAZZ related companies
Pro Ratings for JAZZ
Pro Report PDF for JAZZ
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download JAZZ Pro Report PDF
Pro Strategies Featuring JAZZ
Did Jazz Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
JAZZ Profile
Sector: Healthcare
Industry: Biotechnology
Jazz Pharmaceuticals Inc. is a dynamic specialty biopharmaceutical company that identifies, develops and commercializes innovative products to address unmet medical needs in focused therapeutic areas, always keeping in mind its mission to improve patients’ lives. Headquartered in Dublin, Ireland with locations in California and Pennsylvania, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals. Jazz Pharmaceuticals markets a diverse portfolio of products in the areas of narcolepsy, severe chronic pain, psychiatry and women’s health. The company was founded in 2003.
Other JAZZ Resources
- Company Website
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| JAZZ | 69.66 | +0.16 | +0.23% | 4.125B |
